查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853516

带状疱疹疫苗市场按疫苗类型、年龄层、最终用户、通路和剂量划分－2025-2032年全球预测

Shingles Vaccine Market by Vaccine Type, Age Group, End User, Distribution Channel, Dosage - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，带状疱疹疫苗市场规模将达到 35.6 亿美元，复合年增长率为 8.36%。

关键市场统计数据
基准年2024年 18.7亿美元
预计年份：2025年 20.2亿美元
预测年份 2032 35.6亿美元
复合年增长率（%） 8.36%

全面了解影响带状疱疹疫苗策略的临床、商业性和政策因素，以及这些因素对整个价值链相关人员的影响。

带状疱疹是由水痘-带状疱疹病毒重新运作引起的，由于其发病率随年龄增长而增加，且伴随严重的併发症，如带状疱疹后遗症神经痛，因此仍然是老年人群中一个重要的公共卫生问题。疫苗技术的进步正在重塑预防策略，而支付方和分销管道的变化正在影响疫苗的可及性和接种率。本执行摘要概述了重塑带状疱疹疫苗格局的最重要临床、商业和政策趋势，并重点阐述了这些趋势对研发、生产、分销和患者护理等各个环节的相关人员的影响。

近年来，重组疫苗平台的出现为传统的活病毒疫苗製剂提供了更有效的替代方案，改变了临床建议和免疫接种途径。同时，人口老化带来的人口压力以及对成人免疫接种计画日益重视，也重新激发了公共卫生机构和私人支付者的关注。因此，生产者、医疗服务提供者和经销商正在重新评估其供应策略、服务模式和沟通方式，以最大限度地提高免疫接种覆盖率，并最大限度地减少可预防疾病的负担。

本导言为报告后续分析奠定了基础，包括不断变化的行业格局、累积的政策影响、基于细分的需求驱动因素、区域细微差别、竞争格局、对行业领导者的建议行动以及调查方法，旨在组装一个连贯的、以决策为导向的叙述，以支持在日益复杂的环境中进行战略规划和运营执行。

本文详细描述了影响带状疱疹疫苗接种、采购方式以及整个医疗保健生态系统中相关人员期望的多维度颠覆性因素。

带状疱疹疫苗领域正经历一系列变革性变化，其影响范围不仅限于产品性能，还涵盖分销、支付方参与和患者期望等多个方面。包括改进的重组抗原平台和佐剂系统在内的技术进步，提高了疫苗效力标准，改变了临床指南，并促使医疗系统和临床医生重新评估成人疫苗通讯协定。同时，低温运输物流和数位化分销管道的进步，在扩大疫苗覆盖范围的同时，也为库存管理和供应商选择带来了新的考量。

支付方正转向基于价值的采购和与绩效挂钩的合约模式，奖励生产者证明其产品具有长期的临床和经济效益。这种以结果为导向的报销趋势正在推动对真实世界证据的生成和上市后监测的投入增加。同时，监管机构也正在完善核准和标籤流程，以更好地反映不同年龄层的风险获益比，进而影响国家免疫技术咨询小组和临床学会的建议。

患者的期望和医疗服务提供者的工作流程也在不断变化。同时，初级保健和专科诊所越来越多地将疫苗接种纳入慢性病常规管理。此外，数位药局和电子商务平台在药品取得方面发挥越来越重要的作用，这加速了新型分销模式的采用，也因此需要围绕低温运输保障和用药依从性支持建立新的管治。这些变化共同重塑了整个生态系统的竞争优势和营运重点。

深入分析关税主导的贸易动态如何再形成带状疱疹疫苗供应链决策、采购弹性策略和商业合约方式

关税和贸易措施等政策调整将对整个医药供应链产生下游影响，而美国预计2025年实施的关税政策正迫使相关人员评估其营运的韧性。製造商和经销商正在重新审视关键原料、佐剂和管瓶的筹资策略，以降低进口成本上升和海关延误的风险。为此，采购团队正在拓展供应商基础，加快区域製造商的资格认证，并谈判包含价格保护条款的长期合同，以确保供应的连续性。

物流合作伙伴和低温运输供应商也积极应对潜在的成本变化，他们透过优化路线、整合货物以及探索近岸外包机会来降低关税相关风险。虽然这些营运调整可能会导致某些投入品的前置作业时间延长，但也促使企业加大对国内灌装和包装能力以及冷藏基础设施的投资。由于供应负责人会根据合约承诺和预期需求来确定物资分配的优先顺序，临床医生和医疗系统应预料到采购顺序可能会出现波动。

从商业性角度来看，进口关税的上涨可能会对定价策略、利润结构以及与支付方和经销商的合约方式造成压力。製造商可能会寻求跨通路差异化定价，或将依从性支援和分​​析等服务打包销售，以维持其整体价值提案。监管和政策相关人员可能会加强合作，加快核准替代供应商，并确保国家疫苗接种工作在贸易中断的情况下保持韧性。总而言之，这些累积影响凸显了积极主动的供应链管治、基于情境的规划以及加强公私合营的重要性。

主导了解疫苗类型、年龄层、最终用户、分销管道和接种方式如何相互作用，从而影响疫苗接种率和供应。

对带状疱疹疫苗市场进行细分，有助于了解产品、人群、医疗机构、分销模式和接种方案如何相互作用，从而影响疫苗的推广路径和服务提供模式。疫苗类型可区分重组带状疱疹疫苗和减毒带状疱疹疫苗。重组疫苗在老年族群中疗效较高，并正在影响临床指引；而减毒带状疱疹疫苗在某些临床环境中仍适用。评估产品系列的决策者必须考虑这些疗效和安全性差异，以及影响下游物流的储存和处理要求。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 重组佐剂带状疱疹疫苗在50岁及以上成年人的全球普及率迅速提高
  • 将带状疱疹疫苗接种纳入全国成人常规免疫计划
  • 增加对采用新型mRNA技术的下一代带状疱疹候选疫苗的投资
  • 重点关注新兴市场的疫苗接种计划，以缩小老年人带状疱疹疫苗接种方面的差距
  • 加强消费者教育宣传活动，重点在于新型带状疱疹疫苗的长期有效性与安全性
  • 新兴企业公司与大型製药公司伙伴关係研究，共同开发下一代带状疱疹免疫原。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 带状疱疹疫苗市场（依疫苗类型划分）

  • 重组带状疱疹疫苗
  • 带状疱疹活疫苗

9. 按年龄组别分類的带状疱疹疫苗市场

  • 50至59岁
  • 60至69岁
  • 70岁或以上

第十章 带状疱疹疫苗市场（以最终用户划分）

  • 诊所
    • 社区诊所
    • 私人诊所
  • 医院
    • 综合医院
    • 专科医院

第十一章 带状疱疹疫苗市场（依通路划分）

  • 医院药房
  • 网路药局
    • 数位药房
    • 电商平台
  • 零售药局
    • 连锁药局
    • 独立药房

12. 带状疱疹疫苗市场（依剂量划分）

  • 多剂量
  • 单一剂量

第十三章 带状疱疹疫苗市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 带状疱疹疫苗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国带状疱疹疫苗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • SK chemicals
    • GeneOne Life Science
    • CanSinoBIO
    • Moderna, Inc.
    • Chengdu Institute of Biological Products Co., Ltd.
    • Beijing Institute of Biological Products Co., Ltd.
    • Yuxi Walvax Biotechnology Co., Ltd.
Product Code: MRR-563BF1FCEEC2

The Shingles Vaccine Market is projected to grow by USD 3.56 billion at a CAGR of 8.36% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.87 billion
Estimated Year [2025] USD 2.02 billion
Forecast Year [2032] USD 3.56 billion
CAGR (%) 8.36%

Comprehensive orientation to the clinical, commercial, and policy forces shaping shingles vaccine strategy with implications for stakeholders across the value chain

Shingles, caused by reactivation of varicella-zoster virus, remains a significant public health concern for older adults due to rising incidence with advancing age and the debilitating complications associated with postherpetic neuralgia. Advances in vaccine technology have reshaped prevention strategies, while evolving payer landscapes and distribution shifts are influencing access and uptake. This executive summary consolidates the most salient clinical, commercial, and policy trends that are reshaping the shingles vaccine environment and highlights the implications for stakeholders across development, manufacturing, distribution, and patient care delivery.

In recent years, recombinant vaccine platforms have introduced higher-efficacy alternatives to older live-attenuated formulations, altering clinical recommendations and immunization pathways. At the same time, demographic pressures from aging populations and intensified focus on adult immunization programs are generating renewed attention among public health authorities and private payers. As a result, manufacturers, providers, and distributors are reassessing supply strategies, service delivery models, and communication approaches to maximize coverage and minimize preventable disease burden.

This introduction frames the report's subsequent analysis, which explores transformative shifts in the landscape, cumulative policy impacts, segmentation-driven demand drivers, regional nuances, competitive positioning, recommended actions for industry leaders, and the research methodology underpinning the findings. The intent is to present a coherent, decision-oriented narrative that supports strategic planning and operational execution in an increasingly complex environment.

Detailed exposition of the multi-dimensional disruptive forces altering shingles vaccine adoption, procurement approaches, and stakeholder expectations across health ecosystems

The shingles vaccine landscape is experiencing a set of transformative shifts that extend beyond product performance and into distribution, payer engagement, and patient expectations. Technological advances, including improved recombinant antigen platforms and adjuvant systems, have elevated efficacy benchmarks and altered clinical guidance, prompting health systems and clinicians to reevaluate adult immunization protocols. Concurrently, advances in cold-chain logistics and digital distribution channels are enabling broader access while introducing new considerations for inventory management and supplier selection.

Payer dynamics are shifting toward value-based procurement and performance-linked contracting, which is incentivizing manufacturers to demonstrate long-term clinical and economic benefits. This emphasis on outcome-oriented reimbursement is driving increased investment in real-world evidence generation and post-marketing surveillance. In parallel, regulatory authorities are refining approval and labeling pathways to better reflect age-stratified risk-benefit profiles, which in turn affects recommendations from national immunization technical advisory groups and clinical societies.

Patient expectations and provider workflows are also evolving. Older adults are increasingly informed about vaccine options and seek clear guidance on comparative efficacy and safety, while primary care settings and specialist clinics are integrating vaccination into routine chronic disease management visits. Finally, the growing role of digital pharmacies and e-commerce platforms in medication access is accelerating the adoption of novel distribution models, necessitating new governance around cold-chain assurance and adherence support. Together, these shifts are redefining competitive advantage and operational priorities across the ecosystem.

In-depth analysis of how tariff-driven trade dynamics are reshaping supply chain decisions, procurement resilience strategies, and commercial contracting approaches for shingles vaccines

Policy adjustments such as tariffs and trade measures can create downstream effects across pharmaceutical supply chains, and anticipated tariff actions in the United States in 2025 have prompted stakeholders to assess operational resiliency. Manufacturers and distributors are re-evaluating sourcing strategies for critical raw materials, adjuvants, and vials to mitigate exposure to increased import costs and potential customs-related delays. In response, procurement teams are diversifying supplier bases, accelerating qualification of regional manufacturers, and negotiating longer-term contracts with price protection clauses to preserve continuity of supply.

Logistics partners and cold-chain providers are also adapting to potential cost shifts by optimizing routing, consolidating shipments, and exploring nearshoring opportunities to reduce tariff-related risk. These operational adjustments may increase lead times for certain inputs while prompting investment in domestic fill-and-finish capacity and additional cold-storage infrastructure. Clinicians and health systems should expect potential variations in procurement cadence as supply planners prioritize allocations based on contractual commitments and anticipated demand.

From a commercial perspective, increased import duties can pressure pricing strategies, margin structures, and contracting approaches with payers and distributors. Manufacturers may pursue differentiated pricing across channels or seek to bundle services-such as adherence support or analytics-to sustain overall value propositions. Regulatory and policy stakeholders are likely to intensify collaboration to expedite approvals for alternative suppliers and to ensure that national immunization efforts remain resilient in the face of trade-driven disruptions. Overall, the cumulative effect underscores the importance of proactive supply chain governance, scenario-based planning, and strengthened public-private coordination.

Strategic segmentation-driven insights that decode how vaccine type, age cohorts, end users, distribution channels, and dosing formats interact to influence adoption and delivery

Segmentation of the shingles vaccine landscape illuminates how product, demographic, care setting, distribution patterns, and dosing regimens interact to shape adoption pathways and service delivery models. Based on vaccine type, the environment distinguishes between recombinant zoster vaccine formulations, which have influenced clinical guidelines through higher observed efficacy in older cohorts, and live-attenuated zoster vaccine options that retain relevance in specific clinical circumstances. Decision-makers evaluating product portfolios must consider these efficacy and safety differentials alongside storage and handling requirements that affect downstream logistics.

Based on age group, demand drivers and clinical priorities vary across those aged 50 to 59 years, 60 to 69 years, and those 70 years and above. Younger older adults often present opportunities for proactive preventive outreach and workplace-based vaccination programs, whereas patients aged 70 and above frequently require tailored messaging around comorbidity management and safety signals. Providers must therefore align clinical communications and outreach workflows to the age-stratified risk-benefit calculus in order to improve uptake across cohorts.

Based on end user, delivery pathways bifurcate between clinics and hospitals, with clinics further differentiated into community clinics and private clinics and hospitals further categorized into general hospitals and specialty hospitals. Community clinics often serve as primary access points for preventive care with strong ties to local public health initiatives, while private clinics frequently emphasize patient convenience and bundled preventive services. General hospitals manage large-scale procurement and account for inpatient vaccination needs, whereas specialty hospitals may target vaccination for high-risk patient populations undergoing specific therapies. Each end-user segment requires distinct engagement strategies related to inventory management, clinician education, and reimbursement navigation.

Based on distribution channel, access is facilitated through hospital pharmacies, online pharmacies, and retail pharmacies, with online pharmacies further consisting of digital pharmacies and e-commerce platforms and retail pharmacies including chain pharmacies and independent pharmacies. Hospital pharmacies play a central role in institutional procurement and cold-chain stewardship, while online channels enable convenience and direct-to-consumer fulfillment that must be supported by robust temperature control and authentication protocols. Chain retail pharmacies offer scale and standardized vaccination services, whereas independent pharmacies provide localized patient counseling and flexible scheduling. Channel strategies must therefore integrate service design, cold-chain verification, and digital engagement to ensure both accessibility and adherence.

Based on dosage, delivery considerations span multi-dose and single-dose presentations. Multi-dose presentations can improve supply efficiency in high-volume settings but require stringent cold-chain and multi-dose vial handling procedures, whereas single-dose presentations support point-of-care convenience and reduce wastage in lower-volume environments. Manufacturers and providers should weigh dosing format decisions against clinic throughput, storage constraints, and patient flow dynamics to optimize both clinical outcomes and operational performance.

Comparative regional perspectives that reveal how payer dynamics, infrastructure, and demographic pressures drive differentiated adoption and access strategies across global theaters

Regional dynamics shape both the operational realities and strategic imperatives for stakeholders across the shingles vaccine value chain. In the Americas, public and private payers are increasingly focused on adult immunization schedules and value demonstration, which has accelerated investments in community outreach and integrated care pathways to improve coverage among older adults. Health systems in major markets are leveraging electronic health records and immunization registries to close care gaps, while distribution networks emphasize refrigerated logistics and chain pharmacy partnerships to maximize access.

In Europe, Middle East & Africa, regulatory heterogeneity and variable health system maturity produce a mosaic of adoption scenarios. High-income countries within the region generally align their clinical guidance with emerging efficacy evidence, while middle- and lower-income countries prioritize cost-effective procurement and targeted risk-group immunization. Cold-chain infrastructure variability in certain markets underscores the importance of adaptable product formats and decentralized storage solutions. Cross-border procurement mechanisms and regional regulatory harmonization efforts are increasingly relevant for manufacturers considering supply commitments and pricing strategies.

In the Asia-Pacific region, demographic shifts and expanding healthcare infrastructure are driving heightened demand for adult immunization services. Many markets are scaling up primary care capability and digital health platforms that can facilitate vaccine awareness and appointment scheduling. Local manufacturing capacity and strategic partnerships are likewise being prioritized to enhance supply security and shorten lead times. Across these regional contexts, tailored commercialization models that account for payer structure, distribution maturity, and public health priorities will be essential to achieving sustainable adoption and programmatic impact.

Holistic competitive intelligence highlighting how clinical evidence, operational resilience, and strategic partnerships define leadership in the shingles vaccine landscape

Competitive positioning in the shingles vaccine arena now rests on an integrated set of capabilities that extend beyond clinical differentiation to include supply chain agility, evidence generation, and multi-channel commercial excellence. Leading organizations are investing in post-authorization studies and real-world evidence programs to substantiate long-term effectiveness and to support contracting discussions with payers and health systems. At the same time, operational excellence in cold-chain logistics, fill-and-finish capacity, and supplier diversification has become a strategic priority to mitigate tariff and trade-related risks.

Strategic alliances and manufacturing partnerships are increasingly common as companies seek to broaden geographic reach while containing capital expenditure. Collaborative approaches to distribution-combining hospital procurement networks with retail pharmacy programs and digital fulfillment-are enabling more seamless patient journeys. Marketing efforts are focusing on clear, age-tailored clinical messaging and on clinician-facing education to ensure that vaccine options are integrated into routine care for older adults. Additionally, firms that develop robust adherence and patient-support services are better positioned to demonstrate value to payers and providers under outcome-oriented contracting models.

Intellectual property stewardship, regulatory preparedness, and the capacity to scale commercial operations rapidly during periods of heightened demand further distinguish market leaders. Organizations that align clinical evidence, operational resilience, and stakeholder engagement are most likely to sustain competitive advantage in a dynamic landscape where product efficacy, distribution integrity, and payer alignment converge to determine adoption outcomes.

Action-oriented recommendations that align evidence generation, supply resilience, omnichannel distribution, and stakeholder collaboration to accelerate vaccine access and uptake

Industry leaders should prioritize a set of pragmatic, high-impact actions to navigate the evolving shingles vaccine environment and to capitalize on emerging opportunities. First, organizations must invest in granular real-world evidence generation that demonstrates comparative effectiveness across age bands and clinical subgroups, enabling more compelling value propositions in payer negotiations and clinician adoption discussions. Second, strengthening supply chain resilience through supplier diversification, regional manufacturing partnerships, and validated cold-chain contingency plans will reduce exposure to trade and tariff volatility.

Third, manufacturers and distributors should advance omnichannel distribution strategies that harmonize hospital procurement, retail pharmacy scale, and secure online fulfillment, while ensuring rigorous cold-chain verification and patient adherence support. Fourth, tailored engagement programs for different end users-community clinics, private clinics, general hospitals, and specialty hospitals-will improve uptake by aligning service delivery models and inventory management to specific operational needs. Fifth, commercial teams should develop flexible contracting frameworks and bundled service offerings that reflect payer preferences for outcomes and long-term value, thereby facilitating access in both public and private settings.

Finally, cross-sector collaboration with public health authorities, patient advocacy groups, and clinical societies will amplify outreach efforts and establish clearer adult immunization pathways. By combining evidence generation, operational readiness, channel optimization, and stakeholder alignment, industry leaders can enhance vaccine accessibility and deliver measurable public health impact.

Transparent mixed-methods research approach that integrates expert interviews, regulatory synthesis, and scenario analysis to produce actionable, validated insights for decision-makers

This analysis draws on a mixed-methods research approach designed to integrate primary stakeholder insights with rigorous secondary synthesis and validation. The core methodology combined in-depth interviews with clinical experts, procurement leaders, and distribution partners alongside structured data extraction from public regulatory communications, clinical literature, and policy statements. Interviews were conducted across a range of care settings and regions to capture the operational diversity influencing vaccine delivery and to triangulate emerging themes around adoption barriers and enablers.

Complementing qualitative insights, the research incorporated scenario-based supply chain analysis to assess resilience considerations under different trade and policy conditions. Key assumptions were tested through sensitivity checks and cross-validated with logistics and manufacturing specialists to ensure feasibility and practical relevance. The approach prioritized transparency of sources, explicit documentation of analytic steps, and iterative validation with subject-matter experts to reduce bias and increase applicability for decision-makers.

Ethical considerations were observed in all primary research activities, and data handling adhered to relevant confidentiality and privacy standards. Where applicable, clinical findings referenced peer-reviewed evidence and regulatory guidance to contextualize recommendations. The resulting synthesis emphasizes actionable intelligence and pragmatic pathways for implementation, intended to inform strategic planning rather than provide normative policy prescriptions.

Concise synthesis of strategic imperatives linking clinical advancement, supply resilience, segmentation nuance, and regional variation to operationalize vaccine access goals

In conclusion, the shingles vaccine landscape is at an inflection point where technological advances, demographic shifts, and evolving procurement paradigms intersect to create both challenges and opportunities for stakeholders across the value chain. Recombinant vaccine platforms and improved logistics solutions are raising clinical performance expectations and expanding the scope for broader adult immunization strategies, while tariff and trade dynamics demand more resilient supply chain architectures and adaptive commercial models.

Segmentation nuances across vaccine type, age cohorts, care settings, distribution channels, and dosing formats underscore the importance of tailored approaches that align product attributes with real-world delivery constraints. Regional differences further emphasize the need for customizable engagement models that consider payer structures, infrastructure maturity, and local clinical priorities. Competitive advantage will accrue to organizations that can combine robust evidence generation with operational excellence and flexible contracting to meet the needs of payers, providers, and patients.

Ultimately, proactive planning, strategic collaboration, and investment in both clinical and logistical capabilities will determine which stakeholders are best positioned to improve access and deliver measurable public health impact. This report is intended as a decision-oriented resource to guide such investments and to support evidence-based action across the shingles vaccine ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid global uptake of recombinant adjuvanted shingles vaccines in adults over 50
  • 5.2. Integration of shingles immunization into routine adult vaccination schedules by national agencies
  • 5.3. Growing investment in next generation herpes zoster vaccine candidates leveraging novel mRNA technology
  • 5.4. Heightened focus on vaccine access programs in emerging markets to close shingles immunization gaps in seniors
  • 5.5. Rising consumer awareness campaigns highlighting long term efficacy and safety profiles of newer shingles vaccines
  • 5.6. Collaborative research partnerships between biotech start ups and big pharma to develop next generation zoster immunogens

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Shingles Vaccine Market, by Vaccine Type

  • 8.1. Recombinant Zoster Vaccine
  • 8.2. Zoster Vaccine Live

9. Shingles Vaccine Market, by Age Group

  • 9.1. 50 To 59 Years
  • 9.2. 60 To 69 Years
  • 9.3. 70 Years And Above

10. Shingles Vaccine Market, by End User

  • 10.1. Clinics
    • 10.1.1. Community Clinics
    • 10.1.2. Private Clinics
  • 10.2. Hospitals
    • 10.2.1. General Hospitals
    • 10.2.2. Specialty Hospitals

11. Shingles Vaccine Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
    • 11.2.1. Digital Pharmacies
    • 11.2.2. E-commerce Platforms
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies

12. Shingles Vaccine Market, by Dosage

  • 12.1. Multi Dose
  • 12.2. Single Dose

13. Shingles Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Shingles Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Shingles Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GlaxoSmithKline plc
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. SK chemicals
    • 16.3.4. GeneOne Life Science
    • 16.3.5. CanSinoBIO
    • 16.3.6. Moderna, Inc.
    • 16.3.7. Chengdu Institute of Biological Products Co., Ltd.
    • 16.3.8. Beijing Institute of Biological Products Co., Ltd.
    • 16.3.9. Yuxi Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. SHINGLES VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. SHINGLES VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SHINGLES VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 317. ASEAN SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 318. ASEAN SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 319. ASEAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. ASEAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. ASEAN SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 322. ASEAN SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 323. ASEAN SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 324. ASEAN SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 327. GCC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 328. GCC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 329. GCC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. GCC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. GCC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 332. GCC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 333. GCC SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. GCC SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. GCC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 336. GCC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 337. GCC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 338. GCC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 339. GCC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 340. GCC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 341. GCC SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 342. GCC SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMAC